Patent details

EP3307876 Title: MODIFIED NK-92 CELLS FOR TREATING CANCER

Basic Information

Publication number:
EP3307876
PCT Application Number:
US2016036991
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP168084275
PCT Publication Number:
WO2016201304
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
MODIFIED NK-92 CELLS FOR TREATING CANCER
French Title of Invention:
CELLULES NK-92 MODIFIÉES POUR TRAITER LE CANCER
German Title of Invention:
MODIFIZIERTE NK-92-ZELLEN ZUR BEHANDLUNG VON KREBS
SPC Number:

Dates

Filing date:
10/06/2016
Grant date:
13/09/2023
EP Publication Date:
18/04/2018
PCT Publication Date:
15/12/2016
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
13/09/2023
EP B1 Publication Date:
13/09/2023
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
10/06/2024
Expiration date:
10/06/2036
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
06/09/2023
 
 

Name:
ImmunityBio, Inc.
Address:
9920 Jefferson Boulevard, Culver City, CA 90232, United States (US)

Inventor

Name:
LEE, Tien
Address:
United States (US)

Priority

1

Priority Number:
201562173701 P
Priority Date:
10/06/2015
Priority Country:
United States (US)

2

Priority Number:
201662337044 P
Priority Date:
16/05/2016
Priority Country:
United States (US)

Classification

IPC classification:
C12N 5/0783; C07K 14/54; C07K 14/725; C07K 14/735; C07K 16/28; A61K 35/17; A61K 39/00; A61K 39/395;

Publication

European Patent Bulletin

Issue number:
202337
Publication date:
13/09/2023
Description:
Grant (B1)

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages